Cargando…

Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis

OBJECTIVE: The objective of this meta-analysis was to compare the efficacy and drug safety of tolvaptan with placebo for autosomal dominant polycystic kidney disease (ADPKD). METHODS: The PubMed, Embase, and Cochrane Library databases were searched from inception to September 10, 2021. Eligible stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Jingkui, Xu, Wei, Gong, Lifeng, Xu, Min, Tang, Weigang, Jiang, Wei, Xie, Fengyan, Ding, Liping, Qian, Xiaoli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2022
Materias:	Nephrology - Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958178/ https://www.ncbi.nlm.nih.gov/pubmed/36069961 http://dx.doi.org/10.1007/s11255-022-03353-8

Ejemplares similares

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

Efficacy and safety of tacrolimus versus corticosteroid as initial monotherapy in adult-onset minimal change disease: a meta-analysis
por: Lu, Jingkui, et al.
Publicado: (2022)

Plant-derived compounds for treating autosomal dominant polycystic kidney disease
por: Zhang, Jieting, et al.
Publicado: (2023)

Umbilical hernia in autosomal dominant polycystic kidney disease
por: Hattori, Yoshinari, et al.
Publicado: (2014)

Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
por: Gilbert, Rodney D., et al.
Publicado: (2017)

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
por: Bellos, Ioannis
Publicado: (2021)

Microwave ablation versus radiofrequency ablation for patients with primary and secondary hyperparathyroidism: a meta-analysis
por: Xu, Wei, et al.
Publicado: (2023)

Sturge–Weber syndrome coexisting with autosomal dominant polycystic kidney disease
por: Niemczyk, Mariusz, et al.
Publicado: (2012)

Twenty-Year Survival of Kidney Transplant From a Deceased Donor With Autosomal Dominant Polycystic Kidney Disease
por: Issa, Naim, et al.
Publicado: (2021)

Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
por: Magistroni, Riccardo
Publicado: (2018)

Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
por: Kim, Ha Yeon, et al.
Publicado: (2018)

Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
por: Anderegg, Manuel A., et al.
Publicado: (2020)

Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
por: Jankowska, Magdalena, et al.
Publicado: (2015)

Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease
por: Blanchette, Christopher M., et al.
Publicado: (2014)

A meta-analysis of traditional and functional end-to-side anastomosis in radiocephalic fistula for dialysis access
por: Weigang, Tang, et al.
Publicado: (2021)

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
por: Sans-Atxer, Laia, et al.
Publicado: (2018)

Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
por: Kunizawa, Kyohei, et al.
Publicado: (2018)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Iijima, Hiroko, et al.
Publicado: (2022)

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2023)

Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
por: Kim, Yaerim, et al.
Publicado: (2023)

Comparison of different anastomosis angles in radiocephalic fistula with modified functional end-to-side anastomosis
por: Xu, Wei, et al.
Publicado: (2023)

Parasympathetic activity and total fibrotic kidney in autosomal-dominant polycystic kidney disease patients: a pilot study
por: Lai, Silvia, et al.
Publicado: (2023)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
por: Lanke, Shankar, et al.
Publicado: (2019)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
por: Nakatani, Shinya, et al.
Publicado: (2020)

Multiple Cerebral Aneurysms in an Adult With Autosomal Recessive Polycystic Kidney Disease
por: Gately, Ryan, et al.
Publicado: (2020)

Atypical Clinical Presentation of Autosomal Recessive Polycystic Kidney Mimicking Medullary Sponge Kidney Disease
por: Letavernier, Emmanuel, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide–corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report
por: Zhou, Li, et al.
Publicado: (2022)

Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience
por: Guerra-Torres, Xavier E, et al.
Publicado: (2020)

Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations
por: Moriyama, Tomofumi, et al.
Publicado: (2020)

Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Naranjo, Javier, et al.
Publicado: (2022)

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
por: Lioudis, Michael, et al.
Publicado: (2023)

Feasibility of artificial intelligence-based decision supporting system in tolvaptan prescription for autosomal dominant polycystic kidney disease
por: Shin, Jung Hyun, et al.
Publicado: (2023)

Autosomal dominant polycystic kidney
por: Gudadhe, Rugaved Raghavendra, et al.
Publicado: (2022)

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial
por: Casteleijn, Niek F., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e1jhehuvmnm4o1uo7qvuq3bvbp